$QURE

Springhorn Jeremy P. sold $54K of QURE

Springhorn Jeremy P. sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Springhorn Jeremy P.
Published Jun 12, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The only new fact is the director’s open-market sale details (shares, price, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not change uniQure’s fundamentals.

03

What to watch

The absence of a stated 10b5-1 plan can increase speculation, but without additional context (e.g., prior planned sales, compensation structure) it’s not a reliable signal.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale dated 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure director Jeremy P. Springhorn sold 1,993 shares in an open-market transaction on 2026-06-11, per SEC Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with no accompanying company news (no guidance, trial, deal, or regulatory action) and no 10b5-1 plan disclosed.

Market effects

No clear read-through to the gene-therapy/biotech sector from a single director sale.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to typical institutional float and lacks any fundamental accompanying event, it may be driven by diversification or taxes rather than negative outlook.

Key entities

  • uniQure N.V.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Jeremy P. Springhorn

    Director who sold 1,993 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.